Peptide Therapy 101: A Beginner's Guide to BPC-157, CJC, and More

Peptides are having a moment. Between endurance athletes talking about recovery protocols on podcasts, longevity researchers studying them as aging interventions, and the FDA's 2025 decision to reclassify 14 peptides from Category II to Category I (making legitimate clinical use far more accessible), peptide therapy has moved from fringe biohacker space into mainstream telehealth. This guide explains what peptides actually are, which ones are worth knowing about, and what realistic expectations look like.

What peptides actually are

A peptide is a short chain of amino acids — the same building blocks that make proteins, just much smaller. Your body already produces thousands of peptides that signal for healing, appetite regulation, immune response, sleep, and hundreds of other functions. Therapeutic peptides mimic or enhance these natural signaling molecules.

Peptides vs proteins: Both are made of amino acids. Peptides are typically under 50 amino acids; proteins are longer. Peptides are small enough to signal through specific receptors without the broad regulatory challenges of full protein therapies. Insulin is a peptide. Oxytocin is a peptide. GLP-1 agonists like semaglutide are also peptide-based.

Peptides vs steroids: Completely different. Steroids are lipid-based signaling molecules; peptides are amino-acid chains. They work on different pathways and have different risk profiles. Peptides are generally far milder in side-effect intensity than anabolic steroids, though this varies by peptide.

What peptide therapy is typically used for

The most-researched applications fall into a few categories:

• Recovery — tendon, ligament, and soft-tissue healing (BPC-157, TB-500)
• Growth hormone support — sermorelin, CJC-1295, ipamorelin, tesamorelin; indirect stimulation of natural GH release
• Weight loss — GLP-1 agonists (semaglutide, tirzepatide); also fat-mobilizing peptides like AOD-9604
• Sleep quality — DSIP (delta sleep-inducing peptide); some GH-releasing peptides improve deep sleep as a side benefit
• Anti-aging / longevity — epitalon, MOTS-c, various thymus-derived peptides
• Immune support — thymosin alpha-1; some research in chronic infection recovery
• Cognitive function — semax, selank (nootropic peptides, mostly studied in Russia)

Quality of evidence varies enormously. GLP-1 agonists (semaglutide, tirzepatide) have the strongest evidence because they've gone through full FDA drug approval. Most other peptides are supported by smaller studies, animal data, or practitioner clinical experience rather than large-scale RCTs.

The peptides worth knowing about

BPC-157 (recovery)

Derived from a protein found in human gastric juice. "BPC" stands for Body Protection Compound. Most famous peptide for tissue healing and tendon/ligament recovery.

Claimed effects: Accelerated healing of tendons, ligaments, and gut lining; reduced inflammation; protection of the gut from NSAID damage.

Evidence level: Strong animal data, limited human clinical trials. Widely used in clinical practice based on mechanism and practitioner experience.

Typical use: 250–500 mcg daily, subcutaneous injection, for 4–8 week cycles during active injury rehab.

Who it's for: Athletes with tendinopathy, post-surgical recovery, chronic gut inflammation, connective tissue injuries that haven't responded to rest.

CJC-1295 + Ipamorelin (growth hormone support)

Often stacked together. CJC-1295 is a GH-releasing hormone (GHRH) analog that extends the natural GH pulse; ipamorelin is a GH-releasing peptide (GHRP) that stimulates a GH pulse. Combined, they promote a more natural, sustained elevation of growth hormone than either alone.

Claimed effects: Increased lean muscle, reduced body fat, improved sleep depth, better recovery, modestly improved skin elasticity.

Evidence level: Moderate. Direct effects on GH and IGF-1 levels are well-documented; downstream clinical benefits in body composition are well-supported; longer-term outcomes are less thoroughly studied.

Typical use: 100–300 mcg of each, subcutaneous injection before bed, 5 days on / 2 days off.

Who it's for: Adults over 35 noticing decreased recovery, sleep quality, or body composition; athletes focused on performance and recovery; patients seeking an alternative to direct GH replacement (which is prescription-only and expensive).

Sermorelin (growth hormone support, milder)

Another GHRH analog, shorter-acting than CJC-1295. One of the 14 peptides recently reclassified to Category I, making it more accessible through compounding pharmacies.

Claimed effects: Similar to CJC/ipamorelin — increased GH release — but with a more natural pulsatile profile and shorter half-life.

Evidence level: Well-researched; was FDA-approved as a pediatric GH deficiency treatment (Geref) before being discontinued for commercial reasons (still legally compoundable).

Typical use: 200–500 mcg, subcutaneous injection before bed, nightly.

Who it's for: Similar profile to CJC/ipamorelin; some patients prefer it for the shorter action profile.

Tesamorelin (growth hormone, FDA-approved)

FDA-approved for HIV-associated lipodystrophy (abnormal fat distribution in HIV patients). Used off-label for visceral fat reduction.

Claimed effects: Specific reduction in visceral (deep abdominal) fat; modest improvements in lipid profile.

Evidence level: High — FDA-approved with substantial clinical trial data.

Typical use: 1–2 mg subcutaneous daily.

Who it's for: Patients with elevated visceral fat who haven't responded to standard approaches; specific clinical scenarios.

Semaglutide and Tirzepatide (GLP-1 weight loss)

Peptides by definition. The most clinically validated and widely used peptide therapies today. Covered in depth in our semaglutide vs tirzepatide comparison.

AOD-9604 (fat mobilization)

A fragment of human growth hormone focused specifically on fat metabolism without the broader GH effects.

Claimed effects: Preferential fat mobilization, particularly stubborn fat areas; no significant impact on blood sugar or other GH-mediated metabolic effects.

Evidence level: Moderate — studied in several human trials with mixed results on significance of fat loss beyond placebo.

Typical use: 250–500 mcg, subcutaneous, 5 days per week.

Who it's for: Patients already doing the work (diet, exercise) who want additional fat-loss support without GLP-1-level appetite effects.

DSIP (sleep)

Delta Sleep-Inducing Peptide. Naturally occurs in the brain; administered to support deep (slow-wave) sleep.

Claimed effects: Improved sleep onset, more time in slow-wave sleep, reduced awakenings.

Evidence level: Limited modern research; older Russian and Eastern European studies. Not strong evidence.

Typical use: 100–300 mcg before bed.

Who it's for: Patients struggling with sleep quality despite good sleep hygiene, particularly deep-sleep deficit.

Epithalon / Epitalon (longevity)

A four-amino-acid peptide studied primarily in Russia for telomerase activation and longevity effects.

Claimed effects: Increased telomerase activity, normalized circadian patterns in older adults, possible longevity benefits.

Evidence level: Interesting but primarily from a single Russian research group. Not broadly validated.

Typical use: 5–10 mg over 10–20 day cycles, 1–2 times per year.

Who it's for: Patients interested in longevity protocols; evidence is preliminary so expectations should be modest.

How peptide therapy is actually administered

Most peptides are subcutaneous injections (just like GLP-1 medications). A few are oral or intranasal (BPC-157 can be oral; selank is often intranasal), but injection is more common because peptides are generally degraded in the digestive system.

The technique is identical to injecting semaglutide — small needle, subcutaneous fat, once or twice daily depending on the peptide.

Peptides are typically prescribed in cycles rather than continuous use — 4–12 weeks on, a period off, repeat. Cycling reduces tolerance development and lets the body maintain natural signaling.

What realistic expectations look like

This is where peptide therapy diverges sharply from pharmaceutical expectations. Peptides are subtle, not dramatic.

What peptides generally don't do:

• Produce dramatic, visible changes in a week
• Work in isolation without lifestyle support
• Replace the basics of sleep, nutrition, and training
• Act as substitutes for FDA-approved drugs when the FDA drug is indicated

What peptides can do:

• Accelerate tissue healing when combined with rehab (BPC-157)
• Modestly improve sleep quality (CJC/ipamorelin, sermorelin)
• Support favorable body composition shifts as part of a training + nutrition program
• Help specific clinical situations like visceral fat reduction (tesamorelin)

Peptide therapy works best as adjunct support for people who already have good health fundamentals — consistent training, adequate protein, good sleep hygiene — not as a shortcut that substitutes for any of those.

Cost and availability

Pricing varies widely by peptide:

• BPC-157: $100–200/month for a typical cycle
• Sermorelin: $150–250/month
• CJC-1295 + ipamorelin: $200–400/month depending on dose
• Tesamorelin: $400–900/month (higher cost reflects FDA-approved status)
• Longevity peptides (epitalon, etc.): $150–400 per cycle

Pallas peptide plans start at $149/month for single-peptide programs. Like our GLP-1 plans, pricing is flat and inclusive of provider consultation, medication, and shipping.

The regulatory context (why this matters right now)

Until 2025, many useful peptides existed in a regulatory gray zone — legal to compound but not commonly prescribed outside specialty clinics. In late 2024 and early 2025, the FDA reclassified 14 peptides from Category II (research use only) to Category I (permitted for compounding), which meant legitimate clinical access through US-licensed compounding pharmacies.

The reclassified list includes several of the peptides above (sermorelin, various analogs). This doesn't mean every peptide on the market is legitimate — many are not. It does mean the category is maturing and more patients can access peptide therapy through proper medical channels rather than gray-market sources.

What to look for in a legitimate peptide telehealth program:

1. Licensed US providers prescribing based on health history
2. Medications sourced from US-licensed compounding pharmacies (503A or 503B), not "research chemical" suppliers
3. Clear labeling with peptide name, concentration, lot number, and expiration
4. Provider communication about cycling, monitoring, and expectations

Peptides and GLP-1 therapy together

Many Pallas patients stack peptides with GLP-1 therapy — for example, BPC-157 during a training program while on semaglutide for weight loss, or CJC/ipamorelin to support sleep and recovery during active weight loss.

Stacking can be effective, but requires provider oversight to avoid unnecessary costs, redundant protocols, or interactions. Most patients start with one peptide and add others only after seeing how they respond.

Frequently asked questions

Are peptides safe? Generally yes, when sourced from legitimate medical channels. The larger risks come from: (1) non-medical sources with unknown purity, (2) high doses outside clinical use, and (3) specific contraindications that require medical screening. Properly prescribed peptides in clinical doses have a favorable safety profile in most published research.

Will peptides show up on a drug test? Standard workplace drug screens do not test for peptides. Anti-doping agencies (WADA for Olympic sports, USADA for US athletes) specifically test for many peptides and consider them banned substances. If you're a competing athlete, check your sport's rules before starting any peptide therapy.

How quickly will I notice effects? Varies by peptide. BPC-157 effects on soft-tissue injury can be noticeable within 2–4 weeks. Sleep improvements from CJC/ipamorelin often show up within 1–2 weeks. Body composition changes take 8–12 weeks to become visible. Longevity peptides don't produce noticeable effects on any short timescale.

Do peptides interact with GLP-1 medications? Generally no direct pharmacological interactions. The main consideration is that both are typically injected subcutaneously, so pay attention to site rotation. Your provider confirms specific peptide choices are compatible with your current GLP-1 regimen.

Are peptides covered by insurance? Almost never for non-FDA-approved uses. Tesamorelin has FDA approval for specific indications and may be covered for those patients. Most peptide therapy is cash-pay.

Can I buy peptides online without a prescription? There are companies selling "research peptides" without requiring prescriptions. These are not intended for human use, are not regulated by the FDA, and have documented issues with purity and sterility. Using research chemicals for personal injection carries real risks — wrong dosing, wrong compound, contaminated product, infection. Work with a licensed provider.

---

Bottom line: Peptide therapy is real medicine with growing clinical applications, not a fringe biohack. The best use cases are targeted: recovery from specific injuries (BPC-157), sleep and body composition support (CJC/ipamorelin or sermorelin), or specific clinical needs (tesamorelin). Expect subtle, cumulative benefits — not pharmaceutical-magnitude results. Work with a provider, use legitimate pharmacy sources, and cycle appropriately.